The Latest Breaking News from Pfizer

If you thought social media had a hand in getting Trump elected, watch what happens when you throw AI into the mix

Maybe it's not a full-blown summer surge but COVID numbers are ticking up. For those with concerns due to personal risk factors or the start of the school year, the booster question is top of mind.

A new method called ‘skeletal editing’ offers a hugely simplified way to alter matter, paving the way for world-changing innovations in personalised medicine and sustainable plastics

The pharma industry is poised to witness long-term growth with the introduction of generic medicines and growing demand for personalized and targeted treatments. Hence, fundamentally strong pharma stock AbbVie (ABBV) might be worth buying. However, it might not be the right time to invest in Pfizer (PFE). Keep reading.

A panel of U.S. health advisers is recommending that babies get a new drug to protect them against a respiratory virus

The biggest names in Covid are updating their vaccines for a fall campaign, but that might not bolster Pfizer stock and Moderna stock.

Pfizer stock wavered early Tuesday after the company reported massive sales and earnings declines amid lower demand for Covid products.

Medical journals describe all-cause mortality in randomized controlled trials (RCTs) 

 Evidence the FDA used for those decisions violates at least three safety and efficacy standards from earlier FDA publications

A tornado that ripped through a Pfizer plant in Rocky Mount, N.C., raised worries about shortages of medicines used in hospitals. The drugs include commonly used painkillers and anesthetics.

The markets have been on fire the past couple of weeks. While yesterday’s interest hike took some steam out of the markets, these three stocks and their options are unusually active and worthy of consideration.